• Mutation; VGNC; VGNC:38514; BRAF; None_reported; -; Zygosity=- (PubMed=24035468).
  

PubMed=11217070; DOI=10.1292/jvms.63.83
Ohashi E., Hong S.-H., Takahashi T., Nakagawa T., Mochizuki M., Nishimura R., Sasaki N.
Effect of retinoids on growth inhibition of two canine melanoma cell lines.
J. Vet. Med. Sci. 63:83-86(2001)

PubMed=24035468; DOI=10.1016/j.tvjl.2013.08.003
Ito K., Kobayashi M., Kuroki S., Sasaki Y., Iwata T., Mori K., Kuroki T., Ozawa Y., Tetsuka M., Nakagawa T., Hiroi T., Yamamoto H., Ono K., Washizu T., Bonkobara M.
The proteasome inhibitor bortezomib inhibits the growth of canine malignant melanoma cells in vitro and in vivo.
Vet. J. 198:577-582(2013)

PubMed=27292541; DOI=10.1111/jvp.12336
Kuroki S., Kobayashi M., Tani H., Miyamoto R., Kurita S., Tamura K., Ono K., Washizu T., Bonkobara M.
Selective growth inhibition by suppression of F1Fo ATPase in canine malignant melanoma cell lines.
J. Vet. Pharmacol. Ther. 40:101-104(2017)

PubMed=28283079; DOI=10.1016/j.tvjl.2017.02.001
Yoshitake R., Saeki K., Watanabe M., Nakaoka N., Ong S.M., Hanafusa M., Choisunirachon N., Fujita N., Nishimura R., Nakagawa T.
Molecular investigation of the direct anti-tumour effects of nonsteroidal anti-inflammatory drugs in a panel of canine cancer cell lines.
Vet. J. 221:38-47(2017)